Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
University of Alabama at Birmingham
Study ID
NCT05414500
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Cutaneous T Cell Lymphoma
  • Mycosis Fungoides

Eligibility Criteria

Sex
ALL
Age
19 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Mogamulizumab — DRUG
    Administered IV
  • Brentuximab vedotin — DRUG
    Administered IV

Study Details

This is an open label, single center, non-randomized dose de-escalation phase I study of combination of BV and Mogamulizumab. The primary objective of the study is to assess the safety and tolerability of the combination. The primary objective is also to explore safe dose of combination for future expansion.

Key Dates

Start date
May 1, 2023
Status verified
Apr 2026
Primary completion
Apr 30, 2026
Completion
Jul 31, 2026

Study Design

Enrollment
10 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Cohort
    Fixed dose of Mogamulizumab and dose de-escalation with Brentuximab Vedotin

Primary Outcome Measure

Rates of Adverse Events [ Time Frame: through study completion, an average of 1 year ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Alabama at BirminghamBirminghamAlabama35233
Amit Mehta, MD
[email protected]
205 996 8400

Find similar trials in Birmingham, AL

By research site
University of Alabama at Birmingham· Birmingham, AL

Related Studies